Mets Day 1098 fifth Opdivo infusion; three year mets milestone

Mets Day 1098

Image source:

Today I spent each other amusing-filled day at Johns Hopkins for my 5th nivolumab infusion. The nurse become unable to get a blood return via my port, despite fiddling with it for approximately an hour. She turned me over to a tech for a regular IV. The tech missed on her first stick attempt, then missed on the 2nd. She switched arms and straight away blew my vein on her 0.33 attempt. I suggested that perhaps somebody else try, and she turned me over to a nurse who finally drew blood. Since the lab needed three hours to organize my infusion, I become assured at spending the whole day at Hopkins. Fortunately, my fantastic friend Cynthia came up with me, and we handed the day in conversation.
In the interim, I visited with Dr. Hahn. He said how three new patients had mentioned my weblog regarding the nivolumab clinical trial and wanted in. He become extremely joyful that word become getting out, and become happy with my evangelizing. I should send him a bill for my time.

I asked if he had similarly thoughts on the length of my getting the drug, should I achieve complete recovery (CR). He said that it become not some thing that become spelled out in the clinical trial documents, but rather become a topic to be decided among affected person and doctor. One view become that patients should continue with therapy if it gave the look to be running and doing no harm. But once a affected person has achieved CR, there's no reliable method to degree whether there's ongoing benefit to receiving the therapy. So the opposite view become that, if there become no method to degree whether the therapy become running, it should not be continued.

Since there's almost no data on whether patients with metastatic bladder cancer continue to profit by receiving nivolumab after CR, there's no informed basis to make a choice one method or the opposite. Dr. Hahn suggested that the drug institution might not are seeking to discourage patients from ending using the drug, since (once approved), continuing patients on the drug meant more revenue. But he added that data would accrue with what took place to patients who elected to prevent taking the drug as hostile to those who stayed on it. He added that it would be productive to notice whether the sponsor would enable patients who went off the drug to soar again if their tumors returned. He said he would verify on that. But first, we need to get to CR.

As conventional, the correct infusion become easy. The clinical trial nurse suggested that I can keep away from the long wait if I have my lab work done at a native lab the day before. I'll taker up on that, I suppose.

Meanwhile, the day gone by become the 0.33 year year anniversary that I learned that my cancer had metastasized outside of my bladder. The Kaplan-Meiersurvival curve for metastatic bladder cancer is grim. The NCI publishes measures of cancer survival using its SEER software, and probing it for mets BC data is depressing. Suffice it to say that historic data reveal that, five years after a mets lookup, fewer than 10% of patients are alive. In fact, a 2011 British study came across that fewer that 25% of patients diagnosed with T4 bladder cancer were alive 30 months after lookup. So my hitting the three years mark is reason to celebrate!

More importantly, these data are historic. They do not take into account the progress of immunotherapy treatments such as nivolumab or MPDL3280A. I'm hoping that these new medicine are game-changers, and five years from now we're going to be celebrating a lots higher survival price which, God willing, will include me.

Leave a Reply

Your email address will not be published. Required fields are marked *